Eton Pharmaceuticals, Inc. (ETON)
| Market Cap | 462.60M |
| Revenue (ttm) | 48.33M |
| Net Income (ttm) | -4.58M |
| Shares Out | 26.82M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | 31.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 405,430 |
| Open | 16.94 |
| Previous Close | 16.95 |
| Day's Range | 16.59 - 17.46 |
| 52-Week Range | 3.18 - 21.48 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 29.67 (+72.0%) |
| Earnings Date | May 13, 2025 |
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-s... [Read more]
Financial Performance
In 2024, Eton Pharmaceuticals's revenue was $39.01 million, an increase of 23.29% compared to the previous year's $31.64 million. Losses were -$3.82 million, 308.4% more than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $29.67, which is an increase of 72.00% from the latest price.
News
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric pat...
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydroc...
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patien...
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer ...
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
DEER PARK, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (...
Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Offic...
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter...
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 -
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services –– Now av...
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval –
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Off...
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...